Keywords
How to Cite
Abstract
Psoriasis is a chronic inflammatory disease affecting the skin and joints, characterized by abnormalities in keratinocytes. This condition, affecting 2-3% of the global population, profoundly impacts quality of life and requires early diagnosis and effective management. The article focuses on the review of the etiopathogenic mechanisms and therapeutic approaches, including diagnostic innovations and treatment strategies. Using a comprehensive literature review with data from databases such as PubMed, SciELO, LILACS and Google Scholar, the study highlights the influence of genetic factors, such as HLA-Cw6, and environmental factors, such as stress and obesity, in the pathogenesis of the disease. Diagnosis is essentially clinical, sometimes requiring biopsy, and treatment ranges from topical to biological therapies, the latter targeting specific cytokines such as TNF-α, IL-17 and IL-23. Despite advances, high costs and the need for monitoring are persistent challenges. The research emphasizes the need for an individualized and multidisciplinary therapeutic approach, pointing to the future development of treatments such as JAK inhibitors and advances in personalized medicine for more effective and safer strategies. Continued research is vital to improve clinical outcomes and patients' quality of life.
References
ARMSTRONG, A. W.; READ, C. Psoriasis and cardiovascular disease: epidemiology, mechanisms, and clinical implications. American Journal of Medicine, v. 133, n. 10, p. 1148-1156, 2020.
BOEHNCKE, Wolf-Henning. Etiology and pathogenesis of psoriasis. Rheumatic Disease Clinics, v. 41, n. 4, p. 665-675, 2015.
FELDMAN, S. R. et al. Treatments for psoriatic disease: cost-effectiveness and treatment sequencing. Current Medical Research and Opinion, v. 32, n. 11, p. 1879-1886, 2016.
GORDON, Kenneth B. et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The Lancet, v. 392, n. 10148, p. 650-661, 2018.
GRIFFITHS, C. E. M. et al. Psoriasis. The Lancet, v. 397, n. 10281, p. 1301-1315, 2021.
KAMATA, M.; TATARSKY, B.; NAITO, R. Recent advances in the treatment of psoriasis and psoriatic arthritis with biologics. Journal of Dermatology, v. 47, n. 12, p. 1366-1378, 2020.
KRUEGER, James et al. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study. Journal of Allergy and Clinical Immunology, v. 137, n. 4, p. 1079-1090, 2016.
KUPETS, A.; ZAMMIT, M.; MENTER, A. Safety and efficacy of methotrexate in psoriasis: a critical review. Current Drug Safety, v. 15, n. 2, p. 94-103, 2020.
LUBRANO, E. et al. The burden of psoriatic arthritis. Pharmaceutics, v. 13, n. 10, p. 1554, 2021.
MEASE, P. J. et al. Biological therapy for psoriasis and psoriatic arthritis: perspectives on predicted risks and benefits. British Journal of Dermatology, v. 182, n. 4, p. 815-827, 2020.
MENTER, Alan et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, v. 80, n. 4, p. 1029-1072, 2019.
OGDIE, Alexis; COATES, Laura C.; GLADMAN, Dafna D. Treatment guidelines in psoriatic arthritis. Rheumatology, v. 59, n. Supplement_1, p. i37-i46, 2020.
REICH, Kristian et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo-and active comparator–controlled VOYAGE 2 trial. Journal of the american academy of dermatology, v. 76, n. 3, p. 418-431, 2017.
WU, Jashin J. et al. The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor–α inhibitors versus phototherapy: An observational cohort study. Journal of the American Academy of Dermatology, v. 79, n. 1, p. 60-68, 2018.
KAMIYA, Koji et al. Risk factors for the development of psoriasis. International journal of molecular sciences, v. 20, n. 18, p. 4347, 2019.
MICHALEK, I. M.; LORING, B.; JOHN, S. M. A systematic review of worldwide epidemiology of psoriasis. Journal of the European Academy of Dermatology and Venereology, v. 31, n. 2, p. 205-212, 2017.
PARISI, Rosa et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology, v. 133, n. 2, p. 377-385, 2013.
Romiti, R., Carvalho, A. V. E., Ramos, A. M. O., & Carneiro, S. C. (2017). Epidemiologia da psoríase no Brasil: revisão sistemática e metanálise. Anais Brasileiros de Dermatologia, 92(5), 668–678.
TAKESHITA, Junko et al. Psoriasis and comorbid diseases: epidemiology. Journal of the American Academy of Dermatology, v. 76, n. 3, p. 377-390, 2017.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Beatriz Sartori Thiago Benozzati, Luanna Fonseca Gomes , Bernardo Coradi Burille, Láira Joana Oliveira dos Santos, Giovana Coimbra Zequim, Beatriz Almeida Bardão , Mateus Franzini, Luiz Felix de Figueiredo Neto, Fabrício Salazar Fiorio Marques, Lavínia Agra de Omena